Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Corcept's (CORT) Earnings and Sales Meet Estimates in Q4

2018-02-23 zacks
Corcept Therapeutics Inc.’s (CORT - Free Report) adjusted fourth-quarter 2017 earnings of 19 cents per share were in line with the Zacks Consensus Estimate. The reported figure improved from the year-ago adjusted earnings of 6 cents. (88-0)

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2017 Results - Earnings Call Transcript

2018-02-23 seekingalpha
Good day and welcome to the Corcept Therapeutics' Conference Call. Today’s conference is being recorded. There will be a question-and-answer session following today’s presentation. [Operator Instructions] (29-0)

CORT / Corcept Therapeutics, Inc. FORM 8-K (Current Report)

2018-02-22 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 22, 2018   Corcept Therapeutics Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-50679 77-0487658 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. (29-0)

Corcept Therapeutics Tanked 32% By Trivial Teva Generic Filing, Once In A Blue Moon Biotech Opportunity

2018-02-21 seekingalpha
Teva announced their ANDA submission for a generic formulation of Corcept's extremely profitable Cushing's drug on February 5th. A major overreaction ensued, and Corcept's stock tanked 32%. (29-0)

CORT / Corcept Therapeutics, Inc. / FEDERATED INVESTORS INC /PA/ - 3G/A (Passive Investment)

2018-02-15 sec.gov
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9*) CORCEPT THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 218352102 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i

CORT / Corcept Therapeutics, Inc. / FEDERATED INVESTORS INC /PA/ - 3G/A (Passive Investment)

2018-02-15 sec.gov
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9*) CORCEPT THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 218352102 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i

CORT / Corcept Therapeutics, Inc. / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP (Passive Investment)

2018-02-14 sec.gov
cort_21418.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CORCEPT THERAPEUTICS INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 218352102 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [   ] Rule 13d-1(c) [   ] Rule 13d-1(d) * The r

CORT / Corcept Therapeutics, Inc. / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP (Passive Investment)

2018-02-14 sec.gov
cort_21418.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CORCEPT THERAPEUTICS INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 218352102 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [   ] Rule 13d-1(c) [   ] Rule 13d-1(d) * The r

Corcept Therapeutics - Speculative Buy After Fears On Generic Competition

2018-02-11 seekingalpha
While risks associated to investing in a one-trick pony in biotechnology are very high, Corcept has a few mechanisms of defense including a potential improved product. (152-0)

CORT / Corcept Therapeutics, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-02-09 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) CORCEPT THERAPEUTICS INCORPORATED -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 218352102 -------------------------------------------------------- (CUSIP Number) January 31, 2018 -------------------------------------------------------- (Dat

CORT / Corcept Therapeutics, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-02-09 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) CORCEPT THERAPEUTICS INCORPORATED -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 218352102 -------------------------------------------------------- (CUSIP Number) January 31, 2018 -------------------------------------------------------- (Dat

CORT / Corcept Therapeutics, Inc. / INGALLS & SNYDER LLC - 3G/A (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 9 )* CORCEPT THERAPEUTICS, INC. ----------------------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------------------- (Title of Class of Securities) 218352102 -------------------- (CUSIP Number) 12/31/17 ---------------------------------------------------------------- (Date of Ev

CORT / Corcept Therapeutics, Inc. / INGALLS & SNYDER LLC - 3G/A (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 9 )* CORCEPT THERAPEUTICS, INC. ----------------------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------------------- (Title of Class of Securities) 218352102 -------------------- (CUSIP Number) 12/31/17 ---------------------------------------------------------------- (Date of Ev

CORT / Corcept Therapeutics, Inc. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-08 sec.gov
corcepttherapeuticsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Corcept Therapeutics Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  218352102     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is file


CUSIP: 218352102